SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.26+1.2%Nov 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (2689)1/26/2001 12:43:42 AM
From: Miljenko Zuanic  Read Replies (1) of 52153
 
<<Those researchers felt that the efficacy is VERY conservatively stated and that the morbidity / mortality benefits are quite clear and will prove to be exceedingly positive in ongoing trials.>>

ALXN reported for CABG group, bolus + infusion:

<<Additionally, at 30 days, pexelizumab reduced the death rate from 1.9% in the placebo group to 0.4%, or a relative reduction of 79% (p=NS). >>

Did they commented what were death reasons? MI?
Why is 80% reduction -> p=NS?

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News